BridgeBio Pharma Total Non-Operating Income/Expense 2018-2024 | BBIO
BridgeBio Pharma total non-operating income/expense from 2018 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
BridgeBio Pharma Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$-46 |
| 2022 |
$28 |
| 2021 |
$-10 |
| 2020 |
$-31 |
| 2019 |
$-22 |
| 2018 |
$14 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$27 |
| 2024-06-30 |
$100 |
| 2024-03-31 |
$-37 |
| 2023-12-31 |
$7 |
| 2023-09-30 |
$-22 |
| 2023-06-30 |
$-15 |
| 2023-03-31 |
$-17 |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$-11 |
| 2022-06-30 |
$78 |
| 2022-03-31 |
$-28 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$-12 |
| 2021-06-30 |
$-8 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-8 |
| 2020-09-30 |
$-10 |
| 2020-06-30 |
$-12 |
| 2020-03-31 |
$-2 |
| 2019-12-31 |
$-6 |
| 2019-09-30 |
$-6 |
| 2019-06-30 |
$-5 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
|
| 2018-09-30 |
$-1 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
